James Polewaczyk compensation by year
IDEXX Laboratories Summary Compensation Table · all 4 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Salary | $486,461 | $521,154 | $538,327 | $559,154 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $250,083 | $349,843 | $412,512 | $437,738 |
| Option awards | $749,981 | $1,049,814 | $1,237,583 | $1,312,524 |
| Non-equity incentive | $600,000 | $649,688 | $328,506 | $586,406 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $19,175 | $22,476 | $23,158 | $21,214 |
| Total | $2,105,700 | $2,592,975 | $2,540,086 | $2,917,036 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IDEXX Laboratories Inc DEF 14A filed March 27, 2024, accession 0000874716-24-000075, and prior-year filings. Open the filing on EDGAR.
How this page was built: the IDEXX Laboratories Inc filed document, accession 0000874716-24-000075. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 880 | $488,444 | — |
| RSU | 612 | $339,691 | — |
| RSU | 321 | $178,171 | — |
| RSU | 216 | $119,891 | — |
| RSU | 126 | $69,936 | — |
| Option | 1,238 | — | $206.94 |
| Option | 2,226 | — | $288.78 |
| Option | 3,092 | — | $544.08 |
| Option | 5,404 | — | $505.53 |
| Option | 6,437 | — | $497.43 |
Per the Outstanding Equity Awards at Fiscal Year-End table in IDEXX Laboratories Inc's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
IDEXX Laboratories’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $11,519,309 |
| Brian McKeon | Executive Vice President, Chief Financial Officer and Treasurer | $3,845,065 |
| Tina Hunt | Executive Vice President, Strategy, Sector Development and Global Operations | $3,570,793 |
| Michael Lane | Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | $2,921,361 |
| James Polewaczyk · this page | Executive Vice President and Chief Commercial Officer | $2,917,036 |
The full IDEXX Laboratories compensation record
free company briefThis page is one person within IDEXX Laboratories's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the IDEXX Laboratories proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IDEXX Laboratories's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.